Therapeutic study protocol
| Time . | Groups . | ||||||
|---|---|---|---|---|---|---|---|
| Control . | HAT . | RIT . | PRIT . | PRIT + HAT . | PRIT (ns) . | PRIT (nr) . | |
| − 28 h | — | — | — | HAT-SA | HAT-SA | B3-SA | HAT-SA |
| − 4 h | — | — | — | sCA | sCA | sCA | sCA |
| 0 h | — | HAT | 213Bi-HAT | 213Bi– or90Y–DOTA-biotin | 213Bi–DOTA-biotin | 213Bi–DOTA-biotin | Unlabeled DOTA-biotin |
| 24 h | — | — | — | — | HAT | — | — |
| 7 d | — | HAT | — | — | HAT | — | — |
| 21 d | — | HAT | — | — | HAT | — | — |
| 28 d | — | HAT | — | — | HAT | — | — |
| Time . | Groups . | ||||||
|---|---|---|---|---|---|---|---|
| Control . | HAT . | RIT . | PRIT . | PRIT + HAT . | PRIT (ns) . | PRIT (nr) . | |
| − 28 h | — | — | — | HAT-SA | HAT-SA | B3-SA | HAT-SA |
| − 4 h | — | — | — | sCA | sCA | sCA | sCA |
| 0 h | — | HAT | 213Bi-HAT | 213Bi– or90Y–DOTA-biotin | 213Bi–DOTA-biotin | 213Bi–DOTA-biotin | Unlabeled DOTA-biotin |
| 24 h | — | — | — | — | HAT | — | — |
| 7 d | — | HAT | — | — | HAT | — | — |
| 21 d | — | HAT | — | — | HAT | — | — |
| 28 d | — | HAT | — | — | HAT | — | — |
HAT, humanized anti-Tac; RIT, radioimmunotherapy; PRIT, pretargeting radioimmunotherapy; ns, nonspecific; nr, no radionuclide; HAT-SA, humanized anti-Tac-streptavidin bifunctional conjugate; B3-SA, nonspecific antibody-streptavidin conjugate; sCA, synthetic clearing agent; 213Bi, bismuth 213; 90Y, yttrium 90.